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S308 Poster Session IInot proceed during and after the medical clearance are of particular
interest.
324 donors contacted for work-up (1.3% of the non-cancelled re-
quests) were considered permanently unfit for donation (status DD,
donor deferred), the majority of them by the apheresis centers during
medical clearance. Only 22.8% could be identified by DKMS before
apheresis center clearing.
While 828 donors (3.45% of non-cancelled requests) were tempo-
rarily unavailable (status TU) for medical or non-medical reasons,
the transplant centers could be notified in 61% of those cases prior
to medical clearing. 323 donors contacted (1.3% of the non-can-
celled) withdrew their consent to donate (32.2% during or after
clearance).
We have analyzed demographic factors (age, gender, place of liv-
ing, ethnicity) to identify potential risk factors for failing work-ups.
It showed that 2.0% of female but only 1.1% of male donors with-
drew their consent to donate on the work-up level (p\0.001).While
the average donor age of all non-cancelled requests was 32.9 years, it
was 36.8 years for those donors who were permanently deferred for
medical reasons. Medical reasons included both medical findings
that were unknown to the donor before physical examination and
medical issues known to the donor that could not be covered during
confirmatory typing process. The latter category needs to be specif-
ically addressed to further improve the donor selection process.
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OUTCOMES OF A 1-DAY NONMYELOABLATIVE PREPARATIVE REGIMEN
FOR PRIMARY GRAFT FAILURE AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION
Kanda, J., Horwitz, M.E., Long, G.D., Gasparetto, C., Sullivan, K.M.,
Chute, J.P., Morris, A., Hennig, T., Chao, N.J., Rizzieri, D.A. Duke
University Medical Center, Durham, NC
Primary graft failure after allogeneic stem cell transplantation is
a life-threatening complication because of prolonged neutropenia af-
ter the initial transplantation. A shortened conditioning regimen fol-
lowed by re-transplantation may increase the chance of survival.
Here, we report 11 patients with a median age of 44 (range, 25-67)
years, who received a 1-day reduced-intensity preparative regimen
and subsequent re-transplantation for primary graft failure. The dis-
eases in these patients were as follows: acute myelogenous leukemia/
myelodysplastic syndromes in 6, myeloproliferative diseases in 3,
chronic lymphocytic leukemia in 1, and aplastic anemia in 1. All 11
patients experienced primary engraftment failure following a T-
cell depleted, fludarabine-based nonmyeloablative transplantation
from a haploidentical donor (n 5 6), a matched sibling donor (n 5
1), a matched unrelated donor (n 5 2), or after myeloablative trans-
plantation from dual umbilical cord blood units (n 5 2). The 1-day
preparative regimen for graft failure rescue consisted of 30 mg/m2
fludarabine, 2 g/m2 cyclophosphamide, 20 mg/body alemtuzumab,
and 200 cGy total body irradiation, all delivered 1 day prior to trans-
plantation. Five patients received grafts from the same haploidentical
donor; 5, from a different haploidentical donor; and 1, from the same
matched sibling donor. Out of the 11 patients, 9 engrafted. Of these,
one developed Grade II acute GVHD, and one, Grade I acute
GVHD. At present, 8 out of the 11 patients are alive with a median
follow-up of 9.2 (range, 2.3-28.8) months from the initial transplan-
tation and 7 are in remission. Three patients died, 1 due to infection
and 2 secondary to multi-organ failure. In conclusion, although the
number is small, this case-series suggest that our 1-day preparative
regimen is feasible, leads to successful engraftment in a high propor-
tion of patients, and might be appropriate for patients requiring
immediate re-transplantation after primary graft failure.425
REDUCED INTENSITY VERSUS STANDARD MYELOABLATIVE CONDITION-
ING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN SECOND COM-
PLETE REMISSION
Terwey, T.H.1, Hemmati, P.G.1, Vuong, L.G.1, le Coutre, P.1,
Massenkeil, G.2, D€orken, B.1, Arnold, R.1 1Charite - Universit€atsmedizin
Berlin, Berlin, Germany; 2City Hospital of G€utersloh, G€utersloh,
GermanyIntroduction:We have recently presented data for 93 patients (pts)
transplanted for AML in CR1 where we did not observe a significant
overall survival (OS) difference between reduced intensity (RIC) and
myeloablative conditioning (MAC) (5-yearOS 61% vs. 56%) despite
the fact that RIC pts were significantly older with higher hematopoi-
etic cell transplantation-specific comorbidity index scores (HCT-
CI) (Hemmati et al., Int JHematol. 2010, 91:436-45).Nowwe aimed
to determine whether RIC was similarly safe and effective when
administered in CR2.
Methods:We retrospectively analyzed 38 consecutive AMLpts who
were transplanted in CR2 between 1999 and 2008. 16 pts received
RIC (6x30 mg/m2 FLU, 4x4 mg/kg BU, 4x10 mg/kg ATG) and im-
munosuppression with CSA/MMF and 22 pts received MAC (6x2
Gy TBI and 2x60 mg/kg CY) and CSA/MTX. Donors were HLA-
matched related (5/16 vs. 7/22), -matched unrelated (7/16 vs. 12/
22) or -mismatched (4/16 vs. 3/22) and peripheral blood stem cells
(15/16 vs. 21/22) or bone marrow (1/16 vs. 1/22) were given. Pts
in the RIC group were significantly older (58 years (range: 47-69)
vs. 39 years (20-57), p\ 0.0001) and more pts were HCT-CI high
risk (7/16 vs. 2/22, p 5 0.02). All other patient and treatment
characteristics were similar.
Results: Median follow-up was 49 months (2-107). OS was signifi-
cantly inferior for RIC vs. MAC (multivariate HR 2.50, 95%CI:
1.03-6.11, p5 0.037) with projected OS rates at 1, 2 and 5 years be-
ing 35% vs. 71%, 28% vs. 67% and 28% vs. 52%. Trends for in-
creased cumulative incidence of non-relapse mortality (31% (19%
infection, 12% GVHD) vs. 19% (5% infection, 14% GVHD), p 5
0.3) and of relapse (50% vs. 29%, p 5 0.16) both contributed to
the inferior RIC results. Interestingly, the cumulative incidence of
NIH criteria acute (44% vs. 74%, p 5 0.033) and chronic GVHD
(25% vs. 71%, p 5 0.025) was significantly higher after MAC, sug-
gesting that the lower relapse rate after MAC was not only due to
the higher conditioning intensity but also due to a more potent
GVL effect.
Conclusions: Although our study population was small and subject
to various confounders the current data suggest that in contrast to
CR1 FLU/BU/ATG is not an optimal regimen for AML pts in
CR2 because non-relapse mortality remains substantial and relapse
rates are much higher than with MAC.With reference to the higher
incidence of GVHD after MAC we hypothesize that a modification
of the RIC regimen with better exploitation of the GVL effect may
be beneficial.426
MAJOR ABO MISMATCH INCREASES RED BLOOD CELL TRANSFUSION
REQUIREMENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANTATION USING TOTAL LYMPHOID IRRADIATION AND ANTI-
THYMOGLOBULIN CONDITIONING
Alimoghaddam, K.1, Weiss, S.2, Logan, A.3, Lowsky, R.3, Fontaine, M.2,
Miklos, D.3 1Tehran University of Medical Sciences, Tehran, Islamic Re-
public of Iran; 2Stanford School of Medicine, Palo Alto, CA; 3Stanford
School of Medicine, Palo Alto, CA
Introduction:The clinical impact of ABOmismatch between hema-
topoietic cell transplant (HCT) recipients and their donors remains
controversial. TLI/ATG is a reduced intensity conditioning regimen
associated with low rates of non-relapse mortality. Here, we report
the effects of ABOmismatch on neutrophil and platelet engraftment,
and on red blood cell (RBC) transfusion requirements after TLI/
ATG allo-HCT.
Material and Methods:We analyzed the outcomes of 266 patients
who underwent TLI-ATG conditioned allo-HCT from Jan 2005 to
July 2010, including 139 men and 127 women (median age 57). The
most common indications for HCT were acute leukemia (n 5 91)
and non-Hodgkin lymphoma (n 5 73). Cumulative RBC transfu-
sions through 100 days post-HCT, one year post-HCT, and last fol-
low-up were compared between ABO matched and mismatched
donor-recipient pairs by the Mann-Whitney test.
Results: ABO matched, major mismatched and bidirectionally mis-
matched donor-recipient pairs were observed in 141(53%), 54
(20.3%), and 20(7.5%) of cases. In this cohort following condition-
ing, 149 did not experience an absolute neutrophil count (NC) less
than 500/microliter, and 19 patients did not have NC count less
Poster Session II S309than 1000/microlitter following conditioning. Considering platelets,
157 and 12 of patients did not have platelet count less than 20,000
and 100,000/mcrolitter after transplantation respectively. There
was no difference for engraftement days between ABO mismatched
and matched group. The median RBC transfusion requirement
was 7 units prior to 100 days post-HCT and 8 units through one
year post-HCT and overall follow-up across all recipients.
Table 1. RBC transfusions in ABO major/bidirectional mis-
matched and matched donor-recipient pairs.
Major/bidirectional
All patients missmatch Match P-Valueat 100 days 7.5 8 6 0.11
at 1 year 8 10 8 0.071
overall 8 11 8 0.043A significantly higher total number of RBC transfusions occurred in
major and bidirectional ABO mismatches compared to ABO
matched transplants (11 units vs 8 units; p5 0.043); however, trans-
fusional requirements were only modestly increased throughout the
first year following transplantation in major/bidirectional mismatch
group (10 units vs. 8 units; p 5 0.061). The increase in overall RBC
transfusion was not associated with differences in rates of GVHD,
disease relapse, or overall survival.
Conclusion:ABOmismatchmay be associated with an increased re-
quirement for RBC transfusion after TLI/ATG conditioining.Man-
agement strategies for excessive RBC transfusion after ABO major
mismatched HCT require further study but may target persistent
recipient plasma cells secreting anti donor ABO antibodies.427
OUTCOME OF SECOND ALLOGENEIC STEM CELL TRANSPLANTATION
(SCT) IN PEDIATRIC PATIENTS WITH GRAFT FAILURE OR RECURRENT
LEUKEMIA
Pawlowska, A.B.1, Cheng, J.2, Stiller, T.3, Palmer, J.3, Hafeez, N.1,
Rosenthal, J.1 1City of Hope National Medical Center, Duarte, CA;
2Southern California Kaiser Permanente Medical Group, Los Angeles,
CA; 3City of Hope National Medical Center, Duarte, CA
Both graft failure or leukemia relapse after an allogeneic SCT are
associated with high mortality rate and available treatment options
are limited. We report 22 patients (age 3.9-19.7 years) with hemato-
logical malignancies who received second allogeneic SCT at COH
from 4/2000 – 12/2009 for graft failure (8 patients: AML–3 patients,
ALL-3 patients, CML-1 patient, Lymphoma-1 patient) or recurrent
leukemia (ALL-5 patients, AML-9 patients). Reduced intensity reg-
imen was used in 18 patients; only 4 received myeloablative condi-
tioning. 9 (41%) patients received transplants from the same
donor, and in13 (59%) a different donor was used. Half of the pa-
tients (11) received the second SCT within a year of the first SCT
(median: 391 days, range: 44-1,715). Overall survival for the whole
group at 100 days and 2 years were 77% (60-88%), 45% (35-
55%), respectively. The median follow-up for the 8 (36%) surviving
patients was 4.5 years (range: 0.5-10.6). Patients with graft failure
had superior overall survival (75% at 2 years) compared with recur-
rent disease (28%, p5 0.04) Less advanced disease status (1CR/2CR
vs 3CR/active disease) and diagnosis of non-ALL were associated
with higher likelihood of survival (p 5 0.02, p 5 0.02, respectively).
Survival for patients with less than one year between transplants
(31% at 2 years) did not differ from those receiving the second
SCT later than one year (60%, p 5 0.81). Within 100 days post
transplant 3 patients were diagnosed with CMV, 3 patients with
other viral infection (adeno, VZV, HSV), 12 patients had 23 culture
proven episodes of bacterial infections, 5 patients developed Clos-
tridium difficile enterocolitis and 1 patient was diagnosed with As-
pergillus fumigatus. In summary, second SCT used for graft
failure or leukemia relapse in pediatric patients with hematological
malignancies is associated with acceptable transplant related toxicity
and infection rates. For patients with graft failure the long term out-
come is excellent; for patients with relapsed leukemia second trans-
plant should be offered as a treatment option as it can lead to long
term disease free survival.428
ELEVATED PRE TRANSPLANT SERUM FERRITIN IS ASSOCIATEDWITH IN-
CREASED RISK OF INVASIVE MOLD INFECTION (IMI) AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Dadwal, S.2, Tegtmeier, B.2, James, I.2, Forman, S.1, Pullarkat, V.1
1City of HopeMedical Center, Duarte, CA; 2City of HopeMedical Center,
Duarte, CA
Elevated pre transplant serum ferritin, a measure of iron overload
is associated with various adverse outcomes after allogeneic HSCT
including increased risk of fungal infections. Invasivemold infections
(IMI) are life threatening complications after allogeneic HSCT and
are mostly caused byAspergillus species and Zygomycetes. Small case
series have shown elevated iron stores in HSCT patients who devel-
oped IMI. We examined if elevated serum ferritin prior to HSCT
was associated with increased risk of IMI after allogeneicHSCT. Pa-
tients who underwent allogeneic HSCT from March 2005 through
December 2009, in whom a pretransplant ferritin level was available,
are included in this analysis. Serum ferritin was measured upon ad-
mission for HSCT prior to initiation of conditioning regimen.
Proven or probable IMI was diagnosed according to EORTCMyco-
sis Study Group criteria. Elevated serum ferritin was defined as
values above 1000 ng/ml. Pretransplant ferritin levels were available
in 478 patients. 9 patients (1.9%) had developed IMI at day 30 and 21
patients (4.4%) had IMI at day 100. Among the high ferritin group, 8
of 220 patients developed an IMI within 30 days after HSCT com-
pared to 1 of 258 patients in the low ferritin group (P 5 0.01). 14
of 220 and 7 of 258 patients in the high and low ferritin groups re-
spectively had developed an IMI by day 100 after HSCT (P 5
0.043). The median ferritin level in patents who had IMI at day 30
was 1810 ng/ml compared to 940 ng/ml in those who did not develop
IMI (P 5 0.006). For patients who developed IMI within 100 days
after HSCT, the median ferritin level was 1420 compared to 940
ng/ml for those who were free of IMI. Iron overload as measured
by pretransplant serum ferritin is associated with increased risk of
IMI after allogeneic HSCT. Fungal prophylactic strategies that
cover IMI are particularly important in iron overloaded recipients
of allogeneic HSCT.429
IN VIVO T-CELL DEPLETION (TCD) DOES NOT IMPROVE RATES OF
GRAFT-VERSUS-HOST DISEASE (GVHD) AND TRANSPLANTATION OUT-
COMES IN PATIENTS UNDERGOING PERIPHERAL BLOOD ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANT (AHCT)
Kanate, A.S.1, Osman, S.1, Cumpston, A.2, Hobbs, G.3, Leadmon, S.1,
Bunner, P.1, Gibson, L.1, Tse, W.1, Abraham, J.1, Remick, S.1,
Craig, M.1, Hamadani, M.1 1West Virginia University, Morgantown,
WV; 2West Virginia University, Morgantown, WV; 3West Virginia
University, Morgantown, WV
In vivoTCD is commonly employed to prevent graft rejection and
GVHD in patients undergoing AHCT. Published (but controver-
sial) data suggest possible benefit with TCD in the setting of unre-
lated donor (URD), and HLA-mismatched AHCT. We report
here outcomes for patients who received TCD with transplant
conditioning (TCD group) and compare them with patients who
received T-cell replete allografts (non-TCD group).
The study cohort consists of 150 consecutive patients who under-
went AHCT between 2003 and 2009. All patients received periph-
eral blood allografts. TCD consisted of alemtuzumab (20mg on
days -4 and -1; n5 39) or thymoglobulin 6 mg/kg (total dose) for ab-
lative and reduced intensity conditioning transplants and 7.5 mg/kg
(total dose) for non myeloablative allografts (n 5 51). 4 patients
received Atgam at 30mg/kg on days -5 to -3.
Patient characteristics of TCD and non-TCD groups are shown
in table 1. Significantly more patients in the TCD group had high
risk disease (86.3% v 61.8%, p\ 0.05) and received AHCT from
URD (62.1% v 29.1%, p\0.05). Median follow-up of surviving pa-
tients is 3yrs. There was no significant difference between engraft-
ment kinetics of two groups. The rates of acute GVHD II-IV in
the TCD and non-TCD groups were 42.1% (n 5 40) and 50.9%
(n 5 28) respectively (p0.32).On subgroup analysis rates of acute
GVHD II-IV in the TCD and non-TCDgroups for matched sibling
